Literature DB >> 17622766

Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells.

Jun Wang1, Yan Guo, Bi-Cheng Zhang, Zheng-Tang Chen, Jian-Fei Gao.   

Abstract

Dihydroartemisinin (DHA) is a semisynthesized agent from the artemisinin first extracted from the Chinese plant Artemisia annua. Previous studies have shown that artemisinin derivates, apart from their antimalarial activity, possess antitumor, antiangiogenic, and anti-inflammatory effects. In the present investigation, DHA was found to have a potent ability in influencing lymphatic endothelial cells (LECs) behavior. Murine LECs were isolated from benign lymphangiomas induced by intraperitoneal injection of incomplete Freund's adjuvant and identified by indirect immunofluorescence assay and fluorescence-activated cell sorting analysis to examine the expression of the specific marker VEGFR-3/Flt-4. When LECs were treated with DHA at 10 microg/ml, the growth of LECs was inhibited, and LECs showed typical apoptotic morphological features, with a higher apoptotic rate as compared with the controls. DHA also exerted a significant inhibitory effect on migration and tube-like formation of LECs in a dose-dependent manner. Quantitative RT-PCR further showed that DHA remarkably downregulated the expression of antiapoptotic bcl-2 mRNA, but upregulated that of the proapoptotic gene bax mRNA. In addition, DHA could strongly attenuate the mRNA and protein levels of VEGFR-3/Flt-4. In summary, these findings indicate that DHA may be useful as a potential lymphangiogenesis inhibitor under induction of cell apoptosis, inhibition of the migration, and formation of tube-like structures in LECs. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622766     DOI: 10.1159/000104418

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  14 in total

Review 1.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

2.  Anti-Helicobacter pylori potential of artemisinin and its derivatives.

Authors:  Suchandra Goswami; Rajendra S Bhakuni; Annalakshmi Chinniah; Anirban Pal; Sudip K Kar; Pratap K Das
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

3.  Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.

Authors:  Fengyun Dong; Xia Zhou; Changsheng Li; Suhua Yan; Xianming Deng; Zhiqun Cao; Liqun Li; Bo Tang; Thaddeus D Allen; Ju Liu
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

4.  Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production.

Authors:  Elisabetta Buommino; Adone Baroni; Nunzia Canozo; Marcella Petrazzuolo; Rosario Nicoletti; Antonio Vozza; Maria Antonietta Tufano
Journal:  Invest New Drugs       Date:  2008-10-28       Impact factor: 3.850

5.  Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.

Authors:  Hua Chen; Bei Sun; Shuangjia Wang; Shangha Pan; Yue Gao; Xuewei Bai; Dongbo Xue
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-26       Impact factor: 4.553

Review 6.  Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug.

Authors:  Maria P Crespo-Ortiz; Ming Q Wei
Journal:  J Biomed Biotechnol       Date:  2011-11-22

7.  Anticancer properties of distinct antimalarial drug classes.

Authors:  Rob Hooft van Huijsduijnen; R Kiplin Guy; Kelly Chibale; Richard K Haynes; Ingmar Peitz; Gerhard Kelter; Margaret A Phillips; Jonathan L Vennerstrom; Yongyuth Yuthavong; Timothy N C Wells
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

8.  Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties.

Authors:  Shahid Soomro; Tobias Langenberg; Anne Mahringer; V Badireenath Konkimalla; Cindy Horwedel; Pavlo Holenya; Almut Brand; Canan Cetin; Gert Fricker; Mieke Dewerchin; Peter Carmeliet; Edward M Conway; Herwig Jansen; Thomas Efferth
Journal:  J Cell Mol Med       Date:  2010-07-12       Impact factor: 5.310

9.  Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells.

Authors:  Ying-Ying Lu; Tong-Sheng Chen; Jun-Le Qu; Wen-Liang Pan; Lei Sun; Xun-Bin Wei
Journal:  J Biomed Sci       Date:  2009-02-02       Impact factor: 8.410

10.  M2-polarized macrophages promote metastatic behavior of Lewis lung carcinoma cells by inducing vascular endothelial growth factor-C expression.

Authors:  Bicheng Zhang; Yafei Zhang; Guoqing Yao; Juan Gao; Bo Yang; Yong Zhao; Zhiguo Rao; Jianfei Gao
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.